Mayne Pharma Submits New Drug Application for E4/DRSP to the FDA

Stock Information for Mayne Pharma Group Limited ADR

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mayne Pharma Group Limited ADR

NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent
MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
Mayne Pharma launches another generic oral contraceptive
New Data On Mayne Pharma's Tolsura® (SUBA®-itraconazole) Presented At IDWeek 2020
Mayne Pharma Launches Chlorzoxazone Tablet in the United States
Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US
Mayne Pharma Executes 20 Year License and Supply Agreement for Novel Oral Contraceptive in Australia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.